NASDAQ:BMTI - BioMimetic Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioMimetic Therapeutics logoBioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company's Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company's product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.

Receive BMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for BMTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:BMTI
CUSIPN/A
Phone+1-615-8441280

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

BioMimetic Therapeutics (NASDAQ:BMTI) Frequently Asked Questions

What is BioMimetic Therapeutics' stock symbol?

BioMimetic Therapeutics trades on the NASDAQ under the ticker symbol "BMTI."

Has BioMimetic Therapeutics been receiving favorable news coverage?

Media stories about BMTI stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMimetic Therapeutics earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for BioMimetic Therapeutics.

How do I buy shares of BioMimetic Therapeutics?

Shares of BMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact BioMimetic Therapeutics?

BioMimetic Therapeutics' mailing address is 389 Nichol Mill Lane, FRANKLIN, TN 37067, United States. The biotechnology company can be reached via phone at +1-615-8441280.


MarketBeat Community Rating for BioMimetic Therapeutics (NASDAQ BMTI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about BioMimetic Therapeutics and other stocks. Vote "Outperform" if you believe BMTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.